News

Validation for direct Lp(a)-cholesterol assay

March 10, 2026

A sensitive, high-throughput, immunocapture-based assay for direct quantification of Lp(a)-cholesterol (Lp(a)-C) has been validated for potential use in research studies and clinical trials. The assay uses an apo(a)-specific mAb (LPA4) coupled to magnetic beads to quantify Lp(a)-C in human plasma.

Practical framework for Lp(a) screening and CV risk reduction in Canada

January 20, 2026

A practical framework for Lp(a) screening and cardiovascular (CV) risk assessment and management in Canada highlights inconsistent Lp(a) testing across the country, especially in rural and remote communities, and urges Lp(a) testing to be included on standard laboratory requisitions and automated Lp(a) companion orders at the time of the first lipid panel.

OxPL-apoB and OxPL-apo(a) tests validated for potential use in Lp(a) studies

January 19, 2026

Chemiluminescent ELISA methods for analysing the oxidised phospholipids, OxPL-apoB and OxPL-apo(a), have been validated for use in clinical, translational, and pharmacological research settings – supporting their potential as biomarker tests for oxidative lipid burden in studies of Lp(a) lowering agents.

Lp(a) perceptions in Latin America

January 5, 2026

Awareness of the importance of Lp(a) testing is limited among Latin American (LATAM) physicians and focused on high risk patients, according to responses from 512 physicians working in 20 countries across the region, three quarters in Mexico, who took part in a 36-item Spanish-language online survey.

2025 – A year of new insights in Lp(a) science

December 31, 2025

As 2025 comes to a close, we’re reflecting on a year of important scientific advances and encouraging clinical insights reported on Lp(a) Forum. From deepening our understanding of Lp(a) biology to highlighting important new clinical data, here are some key developments that shaped the field this year. Lp(a) drives atherosclerosis events Elevated Lp(a) levels were […]

Major Lp(a) changes mainly due to technical issues

October 20, 2025

Major Lp(a) changes are due mainly to technical issues rather than biological fluctuations, according to results of a study, published in Atherosclerosis, designed to assess biological variability of Lp(a) concentrations while minimising technical variability.1